Merck, Inc.
🇺🇸United States
Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361)
Phase 3
Completed
- Conditions
- Urothelial Carcinoma Associated 1 RNA, Human
- Interventions
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2023-09-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1010
- Registration Number
- NCT02853305
Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
Phase 3
Active, not recruiting
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 861
- Registration Number
- NCT02853331
Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)
Phase 2
Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2023-04-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 275
- Registration Number
- NCT02853344
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
Phase 1
Completed
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2016-07-18
- Last Posted Date
- 2022-10-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 44
- Registration Number
- NCT02835690
A Study of Ascending Single Doses of Surotomycin in Healthy Participants (MK-4261-008)
Phase 1
Completed
- Conditions
- Clostridium Difficile Associated Diarrhea (CDAD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 40
- Registration Number
- NCT02835105
A Study of Ascending Multiple Doses of Oral Surotomycin in Healthy Participants (MK-4261-009)
Phase 1
Completed
- Conditions
- Clostridium Difficile Associated Diarrhea (CDAD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2016-07-15
- Last Posted Date
- 2016-07-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT02835118
Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151)
Phase 1
Completed
- Conditions
- Melanoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2016-07-01
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 103
- Registration Number
- NCT02821000
Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)
Phase 3
Completed
- Conditions
- Triple Negative Breast Cancer (TNBC)
- Interventions
- Drug: Normale Saline Solution
- First Posted Date
- 2016-06-30
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 882
- Registration Number
- NCT02819518
A Study of the Safety and Efficacy of Sitagliptin Addition During Metformin Up-titration (MK-0431-848)
Phase 3
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2016-06-06
- Last Posted Date
- 2019-02-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 458
- Registration Number
- NCT02791490
Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)
Phase 2
Completed
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 388
- Registration Number
- NCT02787005
© Copyright 2025. All Rights Reserved by MedPath